verified COP 3,6 · D1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Elsevier Ltd

workspace_premium D1 Top 10% — Veterinary (miscellaneous) lock_open Open Access

Vaccine

Vaccine is a journal indexed in SJR in Infectious Diseases and Molecular Medicine with an H index of 222. It has a price of 2395 €. It has a COP Index of 3,6 (best band D1). It is published in English. It has a COP Index of 3,6.

Vaccine focuses its scope in these topics and keywords: vaccine, influenza, vaccination, virus, recombinant, vaccines, immunization, protein, responses, response, ...

ISSN: 0264-410X

Publisher: Elsevier Ltd

Category: Infectious Diseases

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

COP Index trending_up

3,6 D1 Top 10%

7 of 183 journals in Veterinary (miscellaneous)

H-index · SJR 222 · 1,248

Acceptance rate pie_chart

20% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.395 € Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

COP Index

3,6

D1 Top 10%

SJR Impact

1,248

H-index

222

Docs (year)

949

Docs 3y

2941

Total refs

37687

Cites 3y

10938

Citable 3y

2729

Cites/Doc 2y

3.48

Ref/Doc

39.71

Immediate OA

2395 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Perception of risk of vaccine adverse events: a historical perspective

Vaccines and variant CJD

The future of vaccines: an industrial perspective

The expanded programme on immunization calendar in Poland

The antigenic and immunogenic properties of synthetic peptide immunocontraceptive vaccine candidates based on gamete antigens

Teenagers' lifestyle and the risk of exposure to hepatitis B virus

The influence of host factors and immunogenetics on lymphocyte responses to HepageneS vaccination

Primum non nocere in vaccinology

Predictive value of pre-clinical work for vaccine safety assessment

Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization

Potency test of inactivated Newcastle disease vaccines by monoclonal antibody blocking ELISA

Pneumococcal infections in New Zealand

SHOW MORE ARTICLES

Protective antigens of Mycobacterium habana are distributed between peripheral and integral compartments of plasma membrane: a study in experimental tuberculosis of mouse

Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus

Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants

Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines including gelatin

Maternal immunization: the influence of liability issues on vaccine development

Long-term follow-up of hepatitis A vaccination in children

Lessons learned concerning vaccine safety

Inhibition of rotavirus infection in vitro and in vivo by a synthetic peptide from VP4

Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11

Induction of mucosal immunity with a replication-defective adenoviral recombinant

Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model

Improving vaccine safety through the use of immunisation registers and bar code labelled vaccines

FAQs

Vaccine has a COP Index of 3,6 (D1), ranked 7 of 183 in Veterinary (miscellaneous). SJR: 1,248.

Immediate OA APC is 2395 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Vaccine is 20%.

Vaccine

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the COP Index of Vaccine?

What is the APC / publication cost?

What is the acceptance rate?